Clinical Trials Logo

Clinical Trial Summary

Pulse is a randomized non-inferiority phase III clinical trial assessing a new mode of immunotherapy administration based on increased interval time between 2 infusions as maintenance treatment in Pulse arm compared with the conventional administration in Control arm. In both treatment arms, pembrolizumab alone or combined with pemetrexed is allowed as maintenance treatment. Indeed : In Pulse arm : Pembrolizumab 200 mg will be administered to patients every 6 weeks (Q6W) plus, in the absence of contra-indication pemetrexed 500 mg/m^2 will be administered every 3 weeks (Q3W). In control arm : Pembrolizumab 200 mg will be administered to patients every 3 weeks (Q3W) or 400 mg every 6 weeks plus,in the absence of contra-indication pemetrexed 500 mg/m^2 will be administered every 3 weeks (Q3W).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05692999
Study type Interventional
Source Gustave Roussy, Cancer Campus, Grand Paris
Contact Benjamin BESSE
Phone +33(0)1 42 11 62 61
Email Benjamin.BESSE@gustaveroussy.fr
Status Recruiting
Phase Phase 3
Start date March 20, 2023
Completion date January 2029